Data from the phase 3 MANGROVE study support the application for zanubrutinib/rituximab in this mantle cell lymphoma population.
News|Podcasts|June 19, 2021
OncView™ Podcast: Management of Relapsed/Refractory Follicular Lymphoma
Author(s)Matthew Fowler
This special edition of the “Oncology Peer Review On-The-Go” podcast details treatment options and considerations for relapsed/refractory follicular lymphoma.
Advertisement
As part of its OncView™ video series, CancerNetwork® spoke with Sameh Gaballa, MD, of the Moffit Cancer Center, about current and future treatment options and considerations for patients with relapsed/refractory follicular lymphoma (R/R FL).
In the video series, Gaballa discussed the following:
Treatment Options in Relapsed/Refractory Follicular Lymphoma Considerations for Treatment Selection in R/R FL Third-Line Therapy in Follicular Lymphoma Tazemetostat for Relapsed/Refractory Follicular Lymphoma R/R FL: The Role of PI3K Inhibitors Unmet Needs and Looking Ahead in Follicular Lymphoma
To watch more videos in CancerNetwork®’s OncView™ series, visit
Advertisement
Related to this article
In the phase 2 DALY 2-EU trial, zamto-cel prolonged median event-free survival vs R-GemOx in transplant-ineligible relapsed/refractory large B-cell lymphoma.
Rocbrutinib plus R-CHOP yielded a 100% ORR and an 86.7% CR rate in 15 patients with untreated non-GCB DLBCL, warranting randomized evaluation.
Grade 3/4 neurotoxicity in patients prompted a partial clinical hold on the PALISADES-1 and PALISADES-2 trials of KITE-753 in large B-cell lymphoma.
In a phase 2 trial, orelabrutinib plus sintilimab yielded a 60.7% overall response rate in relapsed/refractory primary CNS lymphoma.
Surveillance guidelines limited to cirrhosis may miss up to a third of patients with MASLD-related HCC, according to Daniel Q. Huang, MBBS, PhD.
Hashem B. El-Serag, MD, MPH, discussed fibrosis-based HCC surveillance, ultrasound limits, chemoprevention, and alcohol screening for patients with MASLD.
At The Liver Meeting® 2026, Andrew Moon, MD, MPH, discussed research revealing gaps between clinician and patient priorities in HCC treatment choice.
Advertisement
Advertisement
Trending on CancerNetwork
1
MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance
2
Weighing Immunotherapy for Bridging and Downstaging Before HCC Transplant
3
What Separates a Next-Generation Liver Tumor Board From the Traditional Model?
4
BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC
5